Breakthrough Properties has recently announced that Larkspur Biosciences, Incendia Therapeutics, and Deep Genomics will be occupying prebuilt suites in its newly redeveloped One Canal building located in East Cambridge, Massachusetts. This four-story lab and office building was acquired by Breakthrough in 2021 and spans over 112,000 square feet. It offers flexible lab and office layouts along with a ground floor lounge, fitness center, collaboration spaces, concierge services,and a winter garden with waterfront views. The remaining two floors are expected to be completed by Q1 of 2025.
Strategically situated near Kendall Square and the Charles River on the First Street corridor,this amenity-rich environment provides convenient access to Downtown Boston as well as major biotech companies such as Sanofiand Bristol Myers Squibb.
As an active player in the life science sector with projects spanning over five million square feet across the U.S.and Europe,Breakthrough is a joint venture of Tishman Speyerand Bellco Capital.The firm prioritizes sustainability efforts,targeting LEED Gold certification along with other green certifications for their properties.
The article “Breakthrough Properties Adds Three Biotech Companies to MA R&D Building” originally appeared on Connect CRE.
